Truist Financial Maintains Merus(MRUS.US) With Buy Rating
Truist Financial analyst Asthika Goonewardene maintains $Merus(MRUS.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 32.7% and a total average return of -5.0%
Truist Financial Gives a Buy Rating to Merus (MRUS)
NRG Fusion Market to Grow at a CAGR of 15% Due to Expected First Launch of Merus' Zenocutuzumab and Increased Adoption of NRG1 Fusion Biomarker Testing During the Study Period (2020-2034) | DelveInsight
Foundation Medicine Collaborates With Merus to Advance Treatment Options in NRG1 Fusion-Driven Tumors Using Foundation Medicine's RNA Platform
LifeSci Capital Maintains Merus(MRUS.US) With Buy Rating, Maintains Target Price $100
LifeSci Capital analyst Charles Zhu maintains $Merus(MRUS.US)$ with a buy rating, and maintains the target price at $100.According to TipRanks data, the analyst has a success rate of 40.4% and a
LifeSci Capital Maintains Merus(MRUS.US) With Buy Rating, Raises Target Price to $100
LifeSci Capital analyst Charles Zhu maintains $Merus(MRUS.US)$ with a buy rating, and adjusts the target price from $48 to $100.According to TipRanks data, the analyst has a success rate of 40.4%